www.investacure.com Open in urlscan Pro
35.215.120.137  Public Scan

Form analysis
3 forms found in the DOM

POST

<form id="myFrom" method="POST" data-hs-cf-bound="true">
  <div class="top-form-section">
    <input type="text" name="name" placeholder="NAME">
    <input type="email" name="email" placeholder="EMAIL" required="">
    <input type="submit" id="submitbtn" value="Subscribe">
  </div>
</form>

POST

<form id="myFrom3" method="POST" data-hs-cf-bound="true">
  <input type="text" name="name" placeholder="FULL NAME">
  <input type="email" name="email" placeholder="EMAIL ADDRESS" required="">
  <input type="submit" id="sbmitbtn" value="SUBSCRIBE">
</form>

POST

<form id="myFrom4" method="POST" data-hs-cf-bound="true">
  <div class="top-form-section">
    <input type="text" name="name" placeholder="NAME">
    <input type="email" name="email" placeholder="EMAIL" required="">
    <input type="submit" id="submitbtn" value="Subscribe">
  </div>
</form>

Text Content

InvestAcure

 * CoronaVirus: CareShield Initiative
 * Alzheimer's Conference
 * News & Media
   * InvestAcure News
   * Press Releases
 * Events
 * about




INVESTACURE

We are building a spare change investment platform to help you invest in
companies working on a cure for Alzheimer’s.


Learn More



IMAGINE A WORLD WHERE DRUG COMPANIES ARE OWNED BY MILLIONS OF SPARE CHANGE
INVESTORS COMMITTED TO CURING ALZHEIMER'S


JOIN THE CAUSE, GET ON THE LIST!
WE'LL KEEP YOU IN THE LOOP AND YOU'LL BE THE FIRST TO KNOW WHEN WE LAUNCH!




ALZHEIMER’S MUST BE CURED!

Yet, most major pharmaceuticals have cut back on Alzheimer’s R&D as
unprofitable, while smaller scientist led companies are left struggling for
investment to develop promising scientific discoveries into a cure.

OPPORTUNITY



Alzheimer’s can be reversed in mice and many pathways to a cure have been
discovered

PROBLEM



Investment in companies working on a cure is scarce, stifling progress

SOLUTION



A spare change investment platform to help millions invest in companies working
on a cure for Alzheimer’s

The idea of having millions of people impacted by Alzheimer's join together as
spare change investors, who own stock in drug companies, represents an
innovative and potentially game-changing solution to the "valley of death"
problem in the pharmaceutical industry. If scaled to full potential, it can help
ensure that smaller scientist led drug companies to have the investment and
support of their shareholders needed to pursue the development of cutting edge
scientific breakthroughs into lifesaving drugs. I’m excited to join the team and
do my part in realizing this world-changing vision.


YU-KAI CHOU GAMIFICATION PIONEER, CREATOR OF THE OCTALYSIS FRAMEWORK & AUTHOR OF
ACTIONABLE GAMIFICATION. CXO - HEAD OF UI/UX INVESTACURE, PBC

When Harvey Pitt, former chairman of the SEC, visited MIT and mentioned
InvestAcure as an example of a company using Finance for good, I was intrigued
by the idea as it both spoke to my core values and was inspired by the research
of my colleague, MIT Professor Andrew Lo, on the growing investment bottleneck
stifling the development of lifesaving cures. I believe that Common Need
Investment of spare change by millions committed to curing Alzheimer's is a
potentially game-changing solution to that bottleneck. If successfully
implemented, it can speed the development of lifesaving drugs and save countless
lives. I'm excited to be an advisor to the InvestAcure team and do my part to
help make this a reality.


HEIDI V. PICKETT ASSISTANT DEAN OF THE MIT SLOAN MASTER OF FINANCE PROGRAM

InvestAcure has developed a formidable plan to end the roadblock imposed by
insufficient capital to fund clinical trials necessary to discover effective
cures for Alzheimer Disease. With so many major pharmaceutical companies leaving
the space, it is even more imperative that we activate this approach immediately
if we are to bring cures to families.


GEORGE PERRY, PH.D. DEAN OF COLLEGE OF SCIENCES - UNIVERSITY OF TEXAS AT SAN
ANTONIO & EDITOR OF THE JOURNAL OF ALZHEIMER'S DISEASE

Many advances in research are not pursued by larger drug companies whose
economic models favor palliative care (long-term repeat drug sales) over cures
and drugs over diagnostics while smaller companies struggle to attract
investment. InvestAcure's Common Need Investment model has the potential to
alleviate some of this investment bottleneck. 70 million US adults have a
relative with Alzheimer's. If a small percentage of this affinity group invest
their spare-change, billions of dollars will be freed to fund approaches that
might otherwise be neglected.


DAVID WEILD CO-FOUNDER & VICE CHAIRMAN OF INVESTACURE, PBC AND FORMER CHAIRMAN
OF THE NASDAQ

We can cure Alzheimer’s in our mice every week, but when it comes to clinical
research where real progress needs to be made to cure people, there is simply no
funding available.


HUGO GEERTS, PH.D. FORMER HEAD OF ALZHEIMER'S DRUG DISCOVERY AT JOHNSON &
JOHNSON BELGIUM

We can't afford to sit idly by as research is stalled by a profit-driven agenda.
With InvestAcure, we have a real solution to speed the path to a cure, by
transitioning ownership of drug companies to millions of spare change investors
committed to curing Alzheimer's.


JULIE A. FLEMING FOUNDER OF PURPLE SHERPA

The idea of having millions of people impacted by Alzheimer's join together as
spare change investors, who own stock in drug companies, represents an
innovative and potentially game-changing solution to the "valley of death"
problem in the pharmaceutical industry. If scaled to full potential, it can help
ensure that smaller scientist led drug companies to have the investment and
support of their shareholders needed to pursue the development of cutting edge
scientific breakthroughs into lifesaving drugs. I’m excited to join the team and
do my part in realizing this world-changing vision.


YU-KAI CHOU GAMIFICATION PIONEER, CREATOR OF THE OCTALYSIS FRAMEWORK & AUTHOR OF
ACTIONABLE GAMIFICATION. CXO - HEAD OF UI/UX INVESTACURE, PBC

When Harvey Pitt, former chairman of the SEC, visited MIT and mentioned
InvestAcure as an example of a company using Finance for good, I was intrigued
by the idea as it both spoke to my core values and was inspired by the research
of my colleague, MIT Professor Andrew Lo, on the growing investment bottleneck
stifling the development of lifesaving cures. I believe that Common Need
Investment of spare change by millions committed to curing Alzheimer's is a
potentially game-changing solution to that bottleneck. If successfully
implemented, it can speed the development of lifesaving drugs and save countless
lives. I'm excited to be an advisor to the InvestAcure team and do my part to
help make this a reality.


HEIDI V. PICKETT ASSISTANT DEAN OF THE MIT SLOAN MASTER OF FINANCE PROGRAM

InvestAcure has developed a formidable plan to end the roadblock imposed by
insufficient capital to fund clinical trials necessary to discover effective
cures for Alzheimer Disease. With so many major pharmaceutical companies leaving
the space, it is even more imperative that we activate this approach immediately
if we are to bring cures to families.


GEORGE PERRY, PH.D. DEAN OF COLLEGE OF SCIENCES - UNIVERSITY OF TEXAS AT SAN
ANTONIO & EDITOR OF THE JOURNAL OF ALZHEIMER'S DISEASE

Many advances in research are not pursued by larger drug companies whose
economic models favor palliative care (long-term repeat drug sales) over cures
and drugs over diagnostics while smaller companies struggle to attract
investment. InvestAcure's Common Need Investment model has the potential to
alleviate some of this investment bottleneck. 70 million US adults have a
relative with Alzheimer's. If a small percentage of this affinity group invest
their spare-change, billions of dollars will be freed to fund approaches that
might otherwise be neglected.


DAVID WEILD CO-FOUNDER & VICE CHAIRMAN OF INVESTACURE, PBC AND FORMER CHAIRMAN
OF THE NASDAQ

prev
next



THE INVESTACURE SOLUTION

Automatically round up transactions and invest just spare change in a portfolio
of companies chosen by leading scientists

SIGN UP IN UNDER 5 MINUTES

Set up your InvestAcure investment account online and connect your credit cards

ROUND-UP

Spend like normal. Your day-to-day transactions are rounded up to the nearest
dollar and set aside for investment

INVEST

With the guidance of leading scientists, your spare change is invested in
companies working on a cure for Alzheimer's


IMPACT

When drug companies are owned by millions of spare change investors committed to
curing Alzheimer's....

CURE WOULD BE THE
#1 PRIORITY

BILLIONS IN NEW INVESTMENT TO
EXPLORE EVERY PATH
TO A CURE

DATA FROM RESEARCH AND CLINICAL TRIALS
WOULD BE SHARED, SO WE COULD
BUILD ON EACH OTHER'S EFFORTS AND
COLLABORATE


AS AN INVESTACURE INVESTOR, YOU ACTUALLY OWN SHARES OF THE COMPANIES IN YOUR
PORTFOLIO, SO YOU’RE PART OF THE SOLUTION.

Seventy million Americans have a relative with Alzheimer's - every million spare
change investors can mean $3 billion in investment over 5 years!
That would have 30X the impact of Bill Gates' recently publicized $100 million
commitment to Alzheimer's research.


MEET OUR SCIENTISTS

Your spare change will be invested in a portfolio of companies, chosen with the
guidance of leading Alzheimer's researchers, based on their potential
contribution to advancing the development of a cure.

ADEBOYE ADEJARE, PH.D SCIENTIFIC ADVISOR

NIH and Alzheimer’s Association national panels. Over 50 publications, 5
patents, and more than 100 presentations at conferences.

HUGO GEERTS, PH.D SCIENTIFIC ADVISOR

CSO of In Silico Biosciences, headed Johnson & Johnson Alzheimer’s research and
developed one of only 5 approved Alzheimer’s drugs.

DOUGLAS J MACNEIL, PH.DSCIENTIFIC ADVISOR

A leading expert in early-stage drug discovery directed Exploratory &
Translational Sciences at Merck, scientific board of Alzheimer's Drug Discovery
Foundation, 144 research publications.

GEORGE PERRY, PH.D SCIENTIFIC ADVISOR

Editor-in-Chief of Journal of Alzheimer's, Dean UT-San Antonio, one of the top
most-cited scientists in Neuroscience.

LON SCHNEIDER, PH.DSCIENTIFIC ADVISOR

Director of USC State of California Alzheimer’s Disease Center and the National
Institute on Aging Alzheimer’s Disease Research Center. Editor-in-chief of
Alzheimer’s & Dementia: Translational Research and Clinical Interventions.

PIERRE TARIOT, MD SCIENTIFIC ADVISOR

Director of the Banner Alzheimer’s Institute. Over 350 scientific papers,
including several leading to FDA approval of treatments for Alzheimer's.

J. THOMAS VAUGHAN, PH.D SCIENTIFIC ADVISOR

Columbia University – Director of MR Research – 45 patents – pioneer in
development of MRI technology for diagnosis of Alzheimer’s.

PAUL NEWHOUSE, MDSCIENTIFIC ADVISOR

Director, Center for Cognitive Medicine, Vanderbilt University.


PEACE OF MIND

In building the InvestAcure platform, your peace of mind is our highest
priority. All of your data is protected with 256-bit encryption and never stored
on your phone, tablet or computer.

InvestAcure, PBC is the parent company of InvestAcure, LLC, an SEC-registered
advisor, which will be managing your spare change investment. Our plan is that
your cash and securities will be held in a brokerage account in your name at
Folio Investments, Inc., a member of FINRA & SIPC. Securities in your account
would be protected up to $500,000.

Both InvestAcure, LLC, and Folio are regulated by the SEC, following a strict
set of rules designed to protect investor's accounts.




SIGN UP TODAY AND FIND OUT HOW YOU CAN HELP BUILD A WORLD WITHOUT ALZHEIMER’S.



DISCLOSURE: THE INVESTACURE.COM WEBSITE IS OWNED AND OPERATED BY INVESTACURE,
PBC. INVESTACURE PBC DOES NOT PROVIDE INVESTMENT ADVICE; ANY INVESTMENT ADVICE
IS PROVIDED BY INVESTACURE, LLC AN SEC-REGISTERED INVESTMENT ADVISOR, WHICH IS A
WHOLLY OWNED SUBSIDIARY OF INVESTACURE, PBC.

© 2019 info@investacure.com. All Rights Reserved. 212-655-9865

×

JOIN THE CAUSE, GET ON THE LIST!
WE'LL KEEP YOU IN THE LOOP AND YOU'LL BE THE FIRST TO KNOW WHEN WE LAUNCH!